Lab
Elite Diagnostics Laboratories LLC
Elite Diagnostics Laboratories LLC was paid $5.11M by Medicaid between Jul 2022 and Feb 2024, across 7 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 53% of everything it billed.
33Billing provider infoELITE DIAGNOSTICS LABORATORIES LLC
WOODRIDGE, IL 60517
WOODRIDGE, IL 60517
33aNPI1013671502assigned 10/29/2021
33bProvider typeClinical Medical Laboratory
28Total paid$5.11M
24GClaims52,749
24DCodes billed7
24AFirst – last monthJul 2022 – Feb 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#35 of 235
Median peer was paid$123K
This provider vs. median42×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 5,141 | $211K | |
| 2023 | 15,538 | $608K | |
| 2024incomplete | 32,070 | $4.29M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 53% | 21,449 | 15,509 | $2.72M |
| 87913 | 30% | 10,482 | 8,013 | $1.53M | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 10% | 7,345 | 2,904 | $519K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.2% | 7,348 | 2,901 | $162K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.7% | 5,912 | 2,900 | $137K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 139 | 139 | $34K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | <1% | 74 | 71 | $176.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALREFAE, ALI (LAB OWNER)